Adobe is positioned to benefit from AI, leveraging Firefly and seamless integration to strengthen its creative software moat. Click here to read my analysis.

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...